stockrowCelularity, Inc. (CELU) vs NextCure, Inc. (NXTC)
- Celularity, Inc. CELU 0.76 +4.11%
- NextCure, Inc. NXTC 5.30 +3.52%
Celularity, Inc. and NextCure, Inc. are both Biotechnology companies. Celularity, Inc. and NextCure, Inc. are of similar size ($23.5M and $23.4M). NextCure, Inc. has the higher net margin (0.00% vs −247.7%) and the higher return on invested capital (0.00% vs −462.8%). Across the 15 metrics below, NextCure, Inc. leads on 9 and Celularity, Inc. on 6.
Valuation
Profitability
| Metric | CELU | NXTC | Biotechnology median |
|---|---|---|---|
| Gross margin | 19.23% | 0.00% | 68.51% |
| Operating margin | (264.27%) | 0.00% | 0.00% |
| Net margin | (247.71%) | 0.00% | 0.00% |
| Free cash flow margin | (47.80%) | 0.00% | 0.00% |
| Return on equity | 151.53% | (195.22%) | (51.96%) |
| Return on assets | (42.72%) | (121.60%) | (46.06%) |
| Return on invested capital | (462.77%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack